These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma. Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313 [TBL] [Abstract][Full Text] [Related]
5. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma. Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889 [TBL] [Abstract][Full Text] [Related]
6. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma. Abakay A; Komek H; Abakay O; Palanci Y; Ekici F; Tekbas G; Tanrikulu AC Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1233-41. PubMed ID: 23690193 [TBL] [Abstract][Full Text] [Related]
7. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646 [TBL] [Abstract][Full Text] [Related]
8. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Sharif S; Zahid I; Routledge T; Scarci M Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pretreatment volume-based quantitative Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744 [TBL] [Abstract][Full Text] [Related]
11. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive role of [ Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158 [TBL] [Abstract][Full Text] [Related]
13. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review. Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120 [TBL] [Abstract][Full Text] [Related]
14. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma. Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585 [TBL] [Abstract][Full Text] [Related]
15. Pretreatment serum neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios: Two tumor-related systemic inflammatory markers in patients with thymic epithelial tumors. Wang L; Ruan M; Yan H; Lei B; Sun X; Chang C; Liu L; Xie W Cytokine; 2020 Sep; 133():155149. PubMed ID: 32512341 [TBL] [Abstract][Full Text] [Related]
16. Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma. Doi H; Kuribayashi K; Kitajima K; Yamakado K; Kijima T Clin Lung Cancer; 2020 Jan; 21(1):66-74.e2. PubMed ID: 31551134 [TBL] [Abstract][Full Text] [Related]
17. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma. Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410 [TBL] [Abstract][Full Text] [Related]
19. The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma. Ozmen O; Koyuncu A; Koksal D; Tatci E; Alagoz E; Demirag F; Gokcek A; Arslan N Nucl Med Commun; 2016 Jan; 37(1):43-9. PubMed ID: 26440572 [TBL] [Abstract][Full Text] [Related]
20. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It? Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P Respiration; 2015; 89(6):558-64. PubMed ID: 25966972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]